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Background:  Elevated levels of plasma neurohormones are associated with increased risks of death in heart failure (HF). We compared the 
prognostic values of atrial and brain natriuretic peptides (ANP, BNP) and endothelin-1 (ET-1) in predicting specific modes of death in HF pts.
Methods:  We conducted extended follow-up on 345 fully-treated HF pts (NYHA II-IV, EF: 23 ± 7%). Neurohormones were measured at baseline. 
Primary causes of death were ascertained based on clinical records while blinded to neurohormonal data. Cox hazards models were used to study 
time to death, while conditional logistic models were used to predict cause of death.
Results:  No pts were lost to follow-up. The median duration of alive follow-up was 36.1 months. There were 172 (50%) deaths, of which 70 (20%) 
were from worsening HF (WHF) and 67 (19%) were from sudden death (SD). After adjusting for clinical confounders, N-terminal-pro-atrial natriuretic 
peptide68-98 (Nt-proANP68-98) was the strongest predictor of time to death from WHF (risk-adjusted hazard ratio = 2.02 per log-pg/ml; 95% CI = 
1.38-2.96, p=0.0003), whereas ET-1 was the strongest predictor of time to death from SD (2.29; 95% CI = 1.14-4.61, p=0.02). Both were superior 
to BNP by comparison. Among pts who died, Nt-proANP68-98 more strongly predicted the odds of death from WHF as opposed to SD (risk-adjusted 
odds ratio = 3.74 per log-pg/ml; 95% CI = 1.19-7.69, p=0.0003) than other neurohormones. Nt-proANP68-98 provided the best discrimination 
between pts who died and did not die from WHF (Therneau’s c = 0.822; 95 CI = 0.763, 0.881), while ET-1 provided the best discrimination between 
those who died and did not die from SD (0.742; 95% CI = 0.664, 0.820). Neurohormones modestly improved the discrimination provided by clinical 
assessment alone (0.802 for WHF and 0.716 for SD).
Conclusions:  In HF pts, Nt-proANP68-98 and ET-1 better predicted and discriminated deaths from WHF and SD respectively than BNP. 
Simultaneous profiling with specific neurohormones may better identify pts with higher risk of death from WHF or SD, as compared to other causes, 
in whom more aggresive treatments (ICD, CRT, LVADs) can be targeted.
